This result validates the high specificity of the CRISPR/Cas9 system in targeting the ABL gene, and the superior leukemia therapeutic effects observed both in vitro and in an animal model are anticipated to translate into the clinic in the future. This evidence concerns the gene ABL1 and leukemia.